The Weekly Recap 1/16/26: LSI Alumni Achievements Driving Medtech and Healthtech Forward
In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure new funding, enter new partnerships, receive regulatory clearances, and much more on the road to LSI USA ’26 in Dana Point (March 16–20).
AliveCor
Received FDA clearance for the next generation of its KAI 12L AI technology for the Kardia 12L ECG system, expanding its capabilities to 39 cleared cardiac determinations. The update adds five new determinations, further broadening the diagnostic reach of AliveCor’s portable, AI-powered 12-lead ECG technology.
AtaCor Medical
Entered a collaboration with Abbott to advance a next-generation investigational extravascular implantable cardioverter defibrillator (EV-ICD) system. The partnership will pair AtaCor’s Atala parasternal EV-ICD lead with Abbott’s investigational ICD platform, aiming to deliver lifesaving defibrillation therapy without placing hardware inside the heart or vasculature, potentially reducing long-term lead-related risks.
Biobeat
Entered a strategic collaboration with Kestra Medical Technologies to expand diagnostic insight for patients prescribed the ASSUREⓇ Wearable Cardioverter Defibrillator. The agreement includes an exclusive license, co-development arrangement, and a $5M equity investment, enabling integration of Biobeat’s FDA-cleared, cuffless 24-hour ambulatory blood pressure monitoring technology into Kestra’s cardiac recovery platform.
Distalmotion
Secured a strategic investment from Johnson & Johnson’s JJDC venture arm to support the rollout of its Dexter surgical robot in ambulatory surgery centers (ASCs). The funding builds on Distalmotion’s recent $150M Series G round and advances the company’s strategy to expand access to its modular, ASC-focused soft tissue robotic system across outpatient care settings.
EndoQuest Robotics
Announced new initiatives as part of their collaboration with NVIDIA to integrate NVIDIA IGX Thor, an NVIDIA Blackwell-powered, enterprise-ready platform, into EndoQuest’s next-generation robotic system. The company also announced that the FDA approved initiation of the final stage of EndoQuest’s pivotal PARADIGM trial, enabling enrollment completion ahead of a planned U.S. De Novo submission.
GT Medical Technologies
Announced that the first patients have been enrolled in its BRIDGES U.S. clinical trial evaluating GammaTile for newly diagnosed glioblastoma. The study assesses whether implanting GammaTile at the time of tumor resection, enabling radiation to begin immediately, can improve survival outcomes versus standard postoperative care.
Illumicell AI
Welcomed Daniel Hawkins as an advisor, adding deep medtech leadership experience spanning cardiovascular devices, surgical robotics, and medical imaging. Hawkins, founder of Shockwave Medical and current CEO of Vista AI, brings a track record of building category-defining technologies and scaling them from early development through commercialization.
iotaMotion
Received FDA 510(k) clearance expanding pediatric use of its iotaSOFTⓇ robotic-assisted cochlear implant insertion system to patients four years and older. The clearance broadens access to standardized, controlled electrode array insertion in school-aged children and marks adoption by Cincinnati Children’s Hospital as the first dedicated pediatric center to implement the technology.
This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-weekly-recap-11626-lsi-alumni-achievements-driving-medtech-and-healthtech-forward
Comments
Post a Comment